Letter: should we intensify infliximab in acute severe ulcerative colitis?

Laharie, David; Rivière, Pauline

doi:10.1111/apt.15520

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To view these articles, visit https://doi.org/10.1111/apt.17753 and https://doi. org/10.1111/apt.17873 Matthias Lenfant 1,2 Bram Verstockt 1,2 João Sabino 1,2 Séverine Vermeire 1,2 Marc Ferrante 1,2…”

Section: Ack N O Wle D G E M Entsmentioning

confidence: 99%

“…We read with great interest the letter from Dr. Laharie discussing our study on the predictive role of a segmental endoscopic assessment in ulcerative colitis by means of the modified Mayo endoscopic score (MMES). 1,2 The author focussed on the emerging role of noninvasive monitoring tools such as faecal calprotectin and intestinal ultrasound. Furthermore, he questioned the role of endoscopy as a monitoring tool for ulcerative colitis in future.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply

Lenfant,

Verstockt,

Sabino

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Ack N O Wle D G E M Entsmentioning

confidence: 99%

mentioning

confidence: 99%

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply

Lenfant,

Verstockt,

Sabino

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…For instance, it has been proposed that, in patients with perianal fistulizing CD, higher than usual infliximab TLs are required to induce healing [93][94][95]. It has also been suggested that patients with acute severe ulcerative colitis (ASUC) might benefit from an optimized induction regimen (with an additional infusion at week 1), even though results have been inconsistent so far [96][97][98]. Furthermore, there is evidence that therapeutic levels depend also on the target considered: more ambitious targets might require higher TLs [99,100].…”

Section: Therapeutic Drug Monitoringmentioning

confidence: 99%

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Privitera

Pugliese

Rapaccini

et al. 2021

JCM

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.

show abstract

“…Laharie and Riviere for their thoughtful comments on the use of infliximab rescue therapy and accelerated induction in the setting of steroid-refractory acute severe colitis as reported in our recent paper. 1,2 I fully appreciate their own observation 3 that the 1-year colectomy rates have not declined based on randomised controlled trial evidence.…”

mentioning

confidence: 95%